#Ozempic #GLP1 #WeightLossJourney #ObesityMedicine #semaglutideforweightloss

You can be taking Ozempic every week and still stall out — not because the medication stopped working, but because of habits that quietly cancel it out. In this video, Dr. Mohammed Paika (board-certified in Internal Medicine and Obesity Medicine) breaks down the 10 most common mistakes that stall fat loss, cost muscle, and cause GLP-1 side effects — and exactly what to do instead.

📩 Subscribe to our newsletter for weekly evidence-based insights on GLP-1 science, metabolic health, longevity, nutrition, and healthy recipes. You'll also receive a FREE GLP-1 Diet Cookbook, plus access to our complete resource library, including the GLP-1 Masterclass eBook and our books *The Physician's Physique* and *The Weight Equation*:
https://www.drmohammedpaika.com/newsletter

📘 GLP-1 Masterclass Book (PDF):
https://www.drmohammedpaika.com/glp1ebook

🎓 Complete GLP-1 Weight Loss Masterclass:
https://www.drmohammedpaika.com

👥 Join the Metabolic Health Community on Skool for live Q&As, evidence-based education, accountability, expert support, and a community of people committed to improving their metabolic health:
https://www.skool.com/metabolic-health-community-5316

TIMESTAMPS
00:00 – Intro: why "it stopped working" is usually the wrong diagnosis
01:52 – How GLP-1 medications actually work
03:48 – Mistake #1: Out-dieting the medication
06:02 – Mistake #2: Letting protein become optional
08:41 – Mistake #3: Skipping resistance training
11:04 – Mistake #4: Letting daily movement quietly disappear
14:04 – Mistake #5: Eating heavy combo meals like nothing changed
15:43 – Mistake #6: Getting dehydrated
17:09 – Mistake #7: Drinking your calories
19:08 – Mistake #8: Using the scale as your only scoreboard
21:02 – Mistake #9: Freestyling your dosing
22:57 – Mistake #10: Injecting the same spot every time
24:17 – Full recap
25:13 – Final thoughts + next steps

👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

👍 Like
💬 Comment
📌 Share
🔔 Subscribe for more honest conversations about obesity, metabolism, hormones, and real-world health solutions

References

Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1), NEJM 2021 — nejm.org/doi/full/10.1056/NEJMoa2032183
Jastreboff et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), NEJM 2022 — nejm.org/doi/abs/10.1056/NEJMoa2206038
Lincoff et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT), NEJM 2023 — pubmed.ncbi.nlm.nih.gov/37952131
Neeland et al. Changes in Lean Body Mass with GLP-1-Based Therapies and Mitigation Strategies, Diabetes Obes Metab 2024 — pubmed.ncbi.nlm.nih.gov/38937282
Enhanced Protein Intake on Maintaining Muscle Mass, Strength, and Physical Function in Adults with Overweight/Obesity (meta-analysis) — pmc.ncbi.nlm.nih.gov/articles/PMC8978023

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER
This channel and its content are provided by Dr. Mohammed K. Paika, MD for general educational and informational purposes only. The information presented is not intended as medical advice and does not replace consultation with your personal physician or qualified healthcare professional. Viewing this content does not create a doctor-patient relationship between you and Dr. Paika.Health, nutrition, exercise, and medication topics discussed on this channel may not be appropriate for all individuals. Always consult your own healthcare provider before starting or changing any medication, diet, exercise program, or weight-loss plan, including GLP-1 therapies such as Wegovy, Ozempic, Zepbound, Mounjaro, or similar medications. Exercise and lifestyle changes carry inherent risks. By choosing to follow any information from this channel, you accept full responsibility for your health decisions and outcomes. Dr. Paika and affiliated entities disclaim any liability for injuries, adverse effects, or damages resulting from use or application of information presented in this content.